Tharimmune (THAR) announced that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric ...

Abstract: Systems, eye-mountable devices, and methods that facilitate chronotherapeutic treatment of primary open-angle ...

Powered by member dues and donations, the FSF can only continue to be the cornerstone of a more just digital society with your support. Build a better world with us by matching the average donation of ...

Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...

IMO, this was inevitable as the digitalization of energy infrastructure rapidly expands as the energy transition rolls on. You can't put 1000's of "smart devices" on the grid, which are all running ...